Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
REGULATORY
17 Firms Get Approval for Cymbalta Generics, June Listing Eyed
The Ministry of Health, Labor and Welfare (MHLW) on February 15 approved generic versions of Shionogi’s antidepressant Cymbalta (duloxetine) from 17 companies (40 products) towards the next round of reimbursement listings in June. Eisai’s insomnia med Lunesta (eszopiclone) drew generic…
To read the full story
Related Article
- Aloxi Authorized Generic Now Available Ahead of Gx Contenders
September 8, 2021
- 9 Drugs Face Generic Entries, AGx Debuts for 2 Brands: June Listing
June 17, 2021
- Delays in Cymbalta Generic Launch Stir Worries on Demand Spike for 2 Makers
June 17, 2021
- Will Cymbalta, E Keppra Face Generic Competition This Year? Vesicare, Aloxi Too?
January 20, 2021
REGULATORY
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- Gist of FY2025 Drug Price Revision
December 26, 2024
- Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
- DPP’s Tamaki Rails Against Govt’s Price Revision Decision
December 26, 2024
- Japan Doles Out Orphan Tags for Nihon Servier’s Vorasidenib, 11 More APIs
December 26, 2024
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…